



NIH AIDS Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	HIV-1 PTE Gag Peptide Set
Catalog Number:	11554
Lot Number:	21164
Provided:	320 vials, 1 mg each, lyophilized. For the Peptide Pool of this reagent, please see Cat# 12437.
Description:	This peptide set is designed to permit expression of the most frequent potential T cell epitopes (PTE) of HIV-1 Gag embedded in the sequences of circulating strains of HIV-1 worldwide. The peptides are 15 a.a. in length and contain naturally occurring 9 a.a. sequences that are potential T cell determinants, captured in an unbiased manner (1). For the pooled version of this reagent, please see catalog #12437.
Purity:	>80% purity (HPLC)
Solubility:	See attached table. Peptides that are difficult to solubilize can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. Please note: Cys and Met containing peptide sequences are highly unstable when stored in DMSO for prolonged periods of time; peptide decay is often observed within days to weeks. If DMSO is required, we recommend freshly-prepared working solutions from freeze dried aliquots of these peptides, and prepared pools.
Special Characteristics:	Click here for individual peptide analytical data. Click here for solubility, molecular weight, and purity data. Please Note: The peptides are listed in order of decreasing frequency.
Recommended Storage:	Keep at -20°C lyophilized and -80°C after reconstitution.
Contributor:	DAIDS, NIAID

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

1. Li, F., U. Malhotra, P. B. Gilbert, N. R. Hawkins, A. C. Duerr, J. M. McElrath, L. Corey, and S. G. Self. 2006. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. *Vaccine* 24:6893-6904. [Abstract](#)
2. Malhotra, U., F. Li, J. Nolin, M. Allison, H. Zhao, J. I. Mullins, S. Self, and M. J. McElrath. 2007. Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. *J Virol* 81:5225-5237. [Abstract](#)

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 PTE Gag Peptide Set (Cat# 11554).

Last Updated:

November 20, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.